Quantum-Si (QSI) AI Stock Analysis

• Market Cap: $339.40M
• Dividend Yield: N/A
• Average Volume (3M): 15.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.67
• Revenue Growth: 40.20%
• EPS Growth: -4.07%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 195,552,170
• 10 Day Avg. Volume: 8,380,659
• 30 Day Avg. Volume: 15,519,586
• PEG Ratio: -0.87
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 126.43
• P/FCF Ratio: -4.19
• Enterprise Value/Market Cap: 0.22
• Enterprise Value/Revenue: 23.14
• Enterprise Value/Gross Profit: 44.80
• Enterprise Value/Ebitda: -0.65
• 1Y Price Target: $2.25
• Price Target Upside: 22.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.50 ▼(-18.48% Downside)

Quantum-Si's overall stock score reflects significant financial challenges, particularly in profitability and cash flow management. Technical analysis indicates potential bearish momentum, and valuation metrics are unattractive due to ongoing losses. However, the company's focus on innovation and strategic product developments, as highlighted in the earnings call and corporate events, provide some optimism for future growth.

Positive Factors

Product Innovation

The successful testing of the Proteus prototype marks a significant step in product innovation, potentially enhancing Quantum-Si's market position in proteomics.

Academic Partnerships

Expanding academic partnerships strengthens Quantum-Si's market reach and validates its technology, fostering long-term growth opportunities.

Cost Management

Effective cost management, evidenced by reduced operating expenses, supports financial stability and allows for continued investment in innovation.

Negative Factors

Profitability Challenges

Ongoing profitability issues, with negative margins and declining revenue, pose risks to Quantum-Si's financial health and sustainability.

Long Sales Cycle

Extended sales cycles in key segments can delay revenue realization, impacting cash flow and growth momentum in the competitive biotech industry.

Lease Termination Costs

Significant costs from lease termination impact financials, highlighting challenges in managing operational expenses and strategic asset allocation.

Quantum-Si Business Overview & Revenue Model

Company Description

Quantum-Si (QSI) is a biotechnology company focused on advancing the field of proteomics through its proprietary next-generation protein sequencing technology. Operating primarily in the life sciences sector, Quantum-Si aims to unlock the potential of proteins to drive discoveries in drug development, diagnostics, and personalized medicine. The company's core product offerings include its protein sequencing platform and related software solutions, which enable researchers and clinicians to analyze protein structures and functions with unprecedented accuracy and speed.

How the Company Makes Money

Quantum-Si generates revenue through multiple streams including the sale of its protein sequencing systems and reagents, as well as software licenses for its analytical tools. The company targets academic and commercial research institutions, pharmaceutical companies, and biotechnology firms that require advanced proteomic analysis capabilities. Significant partnerships with academic institutions and research organizations help to enhance its product development and validate its technology, potentially leading to further revenue opportunities. Additionally, QSI may explore collaborations for joint research projects or co-development agreements that can contribute to its earnings.

Quantum-Si Financial Statement Overview

Summary

Quantum-Si faces significant financial challenges, particularly in terms of profitability and cash flow. The income statement reveals negative net profit margins and declining revenue growth. The balance sheet shows low leverage but negative return on equity, and the cash flow statement highlights negative operating and free cash flow. Despite a stable financial structure, profitability and cash management need strategic improvements.

Income Statement

Quantum-Si's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a gross profit margin of 53.17%, indicating some efficiency in managing production costs. However, the company struggles with profitability, as evidenced by a net profit margin of -31.20% and an EBIT margin of -32.43%. The revenue growth rate is negative, at -6.89%, suggesting declining sales. Overall, the company faces profitability issues that need addressing.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.05, indicating conservative leverage. However, the return on equity is negative at -47.64%, reflecting the company's inability to generate profit from shareholders' equity. The equity ratio is strong, with stockholders' equity making up a significant portion of total assets. While the company maintains a stable financial structure, profitability remains a concern.

Cash Flow

The cash flow statement highlights a challenging cash position, with negative operating cash flow and free cash flow. Despite this, the free cash flow to net income ratio is positive at 1.04, indicating that the company is generating some cash relative to its net losses. The free cash flow growth rate is positive at 9.18%, showing some improvement. However, the operating cash flow to net income ratio is negative, suggesting operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.18M	3.06M	1.08M	0.00	0.00	0.00
Gross Profit	1.64M	1.60M	488.00K	0.00	0.00	0.00
EBITDA	-113.96M	-103.98M	-91.80M	-111.77M	-93.94M	-35.80M
Net Income	-116.85M	-101.01M	-95.96M	-132.44M	-94.99M	-36.61M
Balance Sheet
Total Assets	260.13M	247.87M	298.25M	391.49M	503.23M	40.59M
Cash, Cash Equivalents and Short-Term Investments	225.84M	209.60M	257.74M	351.31M	471.30M	36.91M
Total Debt	4.61M	12.95M	15.30M	17.45M	8.08M	1.75M
Total Liabilities	24.97M	32.45M	26.63M	32.78M	26.19M	4.50M
Stockholders Equity	235.16M	215.42M	271.62M	358.71M	477.03M	36.09M
Cash Flow
Free Cash Flow	-105.22M	-92.38M	-99.31M	-101.30M	-72.58M	-33.03M
Operating Cash Flow	-101.25M	-87.80M	-94.04M	-90.56M	-66.81M	-32.57M
Investing Cash Flow	-41.27M	-32.67M	143.43M	137.19M	-450.94M	-461.00K
Financing Cash Flow	131.16M	35.88M	149.00K	1.91M	516.63M	37.01M

Quantum-Si Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Negative. The current price of 1.84 is above the 20-day moving average (MA) of 1.35, above the 50-day MA of 1.73, and above the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 38.70 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QSI.

Quantum-Si Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$122.17M	-1.58	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FHTX	51 Neutral	$199.55M	-2.85	―	―	-3.91%	37.89%
QSI	50 Neutral	$339.40M	―	-52.44%	―	40.20%	-4.07%
DSGN	47 Neutral	$355.36M	-5.58	-29.83%	―	―	-40.26%
TNYA	36 Underperform	$141.53M	-1.08	-96.44%	―	―	46.68%
ERAS	34 Underperform	$1.02B	―	-32.00%	―	―	45.66%

Quantum-Si Corporate Events

Quantum-Si Unveils Proteus Advancements at Investor Day

On November 19, 2025, Quantum-Si held its Investor & Analyst Day, presenting significant advancements in its Proteus program. The company highlighted the Proteus platform’s capabilities in deep protein analysis, automation, and affordability, which are expected to enhance proteomics research accessibility and efficiency. The Proteus platform, set for launch by the end of 2026, promises superior sequencing output and quality compared to existing technologies, positioning Quantum-Si as a leader in the proteomics field.

Quantum-Si Enters Sales Agreement with Leerink Partners

On September 26, 2025, Quantum-Si Incorporated entered into a Sales Agreement with Leerink Partners LLC to potentially offer and sell up to $100 million of its Class A common stock. The agreement allows for sales at the company’s discretion and is contingent upon the effectiveness of a shelf registration statement filed with the SEC. The arrangement provides flexibility in stock sales, with Leerink Partners acting as sales agent, and includes provisions for commissions and legal expense reimbursements. This strategic move could impact Quantum-Si’s market presence and financial strategy, although the company is not obligated to sell any shares.

Quantum-Si Terminates Lease Agreement with Winchester Office

Quantum-Si Incorporated and Winchester Office LLC have agreed to terminate their lease agreement for premises in New Haven, CT, originally set to expire in 2032. As part of the settlement, Quantum-Si will pay a termination fee of $11 million, adjusted for credits, and will have no further rent obligations after September 23, 2025.